Isotretinoin Generic denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for isotretinoin generic are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Issue a "Not FDA-Approved" Denial for Generic Isotretinoin — and Why This Is Almost Certainly an Error

Generic isotretinoin has received FDA approval as therapeutically equivalent to the reference listed drug. A "not FDA-approved" denial for generic isotretinoin is almost always a processing or coding error — not a valid clinical or regulatory determination. Common causes include:

• The claim was submitted with a drug code that does not match the FDA-approved labeling.
• The plan's system has not been updated to recognize a recently approved generic formulation.
• The denial was generated from an incorrect cross-reference between the NDC (national drug code) and the formulary database.

This type of denial should be resolved quickly on appeal with the right documentation.

## The Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): File an internal appeal immediately, providing FDA approval documentation. The plan is required to conduct a full-and-fair review.
• External review: If the internal appeal fails (unlikely in this scenario), external review is available and the external reviewer will apply FDA approval status — not the plan's internal database — as the standard.
• Expedited option: If the patient is enrolled in iPLEDGE and the dispensing window is time-sensitive, document this and request expedited processing.

## Timeline

1. Contact the pharmacy and the prescriber to confirm the correct NDC and drug code were submitted. 2. File internal appeal with FDA approval documentation. 3. Escalate to external review if needed.

## Documentation to Gather

• FDA approval confirmation: Reference the FDA's Drugs@FDA database or the approved labeling for the specific generic product. Include the Abbreviated New Drug Application (ANDA) number if available, or simply cite that the product is listed in the FDA's Orange Book as therapeutically equivalent.
• Prescriber letter confirming that the prescribed product is an FDA-approved generic formulation of isotretinoin.
• Pharmacy dispensing records confirming the exact product dispensed or prescribed (including NDC).
• iPLEDGE documentation showing the prescription is within the program requirements.
• Denial letter — obtain the specific policy or criterion UHC used to make the "not FDA-approved" determination, so your appeal addresses it directly.

## Criteria-Mapping Structure

In your appeal, state plainly: (1) the specific generic product prescribed is listed in the FDA Orange Book as an approved therapeutically equivalent to the reference listed isotretinoin product; (2) it is prescribed for the FDA-approved indication; (3) the patient is enrolled in iPLEDGE as required. Request that UHC identify the specific basis for the denial, including which FDA regulation or plan policy the generic product allegedly fails to satisfy. In most cases, presenting this documentation results in reversal at the first internal review level.